newsfilter
← Earnings
Earnings Releases·

Prothena Corporation — Third Quarter 2026 Earnings Summary

  • Net loss narrowed significantly to $16.5 million in Q3 2026 from $36.5 million in the prior year period, with full-year 2026 net loss projected between $25 million and $30 million; R&D and G&A expenses declined substantially compared to 2025 levels.
  • Revenue totaled $0.6 million in Q3 2026 and $52.7 million for the first nine months, driven by $50.0 million in milestone payments from Novo and $2.66 million in collaboration revenue from Bristol Myers Squibb.
  • Company guidance indicates full-year 2026 net cash used in operating and investing activities will range from $18 million to $23 million, with an expected cash balance of approximately $259 million by year-end.
  • Strategic progress includes ongoing Phase 3 trials for Prasinezumab (Roche) and Coramitug (Novo) with 2029 completion targets, a Phase 2 readout for Moponetug (BMS) expected in H1 2027, and a $26.6 million share repurchase activity in the first nine months of 2026.
Company
PROTHENA CORP PUBLIC LTD CO
Sector
Healthcare
Industry
Biotechnology